γ-aminobutyric acid and glutamate/glutamine alterations of the left prefrontal cortex in individuals with methamphetamine use disorder: a combined transcranial magnetic stimulation-magnetic resonance spectroscopy study.
Methamphetamine use disorder
magnetic resonance spectroscopy
prefrontal cortex
repetitive transcranial magnetic stimulation (rTMS)
γ-aminobutyric acid (GABA)
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
entrez:
2
5
2020
pubmed:
2
5
2020
medline:
2
5
2020
Statut:
ppublish
Résumé
GABAergic and glutamatergic neurotransmitter systems are critical in the pathophysiology of addiction and represent potential targets for repetitive transcranial magnetic stimulation (rTMS). This study aims to investigate changes in γ-aminobutyric acid (GABA) levels, the combined resonance of glutamate and glutamine (Glx) in the left dorsolateral prefrontal cortex (DLPFC), and cognitive function of patients with methamphetamine dependence following rTMS intervention, using proton magnetic resonance spectroscopy ( Fifty methamphetamine-dependent patients were randomized to a 4-week course of active or sham rTMS, with We observed significant reductions of GABA/NAA concentration in the active group and Glx/NAA concentration in the group receiving sham rTMS. There was a significant association between changes in GABA concentration and problem solving/error monitoring. The effect of rTMS on cognitive function in individuals with methamphetamine dependence may be related to changes in GABA levels in the prefrontal cortex, and warrants further investigation.
Sections du résumé
BACKGROUND
BACKGROUND
GABAergic and glutamatergic neurotransmitter systems are critical in the pathophysiology of addiction and represent potential targets for repetitive transcranial magnetic stimulation (rTMS). This study aims to investigate changes in γ-aminobutyric acid (GABA) levels, the combined resonance of glutamate and glutamine (Glx) in the left dorsolateral prefrontal cortex (DLPFC), and cognitive function of patients with methamphetamine dependence following rTMS intervention, using proton magnetic resonance spectroscopy (
METHODS
METHODS
Fifty methamphetamine-dependent patients were randomized to a 4-week course of active or sham rTMS, with
RESULTS
RESULTS
We observed significant reductions of GABA/NAA concentration in the active group and Glx/NAA concentration in the group receiving sham rTMS. There was a significant association between changes in GABA concentration and problem solving/error monitoring.
CONCLUSIONS
CONCLUSIONS
The effect of rTMS on cognitive function in individuals with methamphetamine dependence may be related to changes in GABA levels in the prefrontal cortex, and warrants further investigation.
Identifiants
pubmed: 32355791
doi: 10.21037/atm.2020.02.95
pii: atm-08-06-347
pmc: PMC7186735
doi:
Types de publication
Journal Article
Langues
eng
Pagination
347Informations de copyright
2020 Annals of Translational Medicine. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Brain Stimul. 2018 Jul - Aug;11(4):797-805
pubmed: 29519725
Drug Alcohol Depend. 2017 Jun 1;175:84-91
pubmed: 28410525
Cereb Cortex. 1993 Sep-Oct;3(5):361-72
pubmed: 8260806
Biol Psychiatry. 2018 Aug 1;84(3):180-192
pubmed: 29102027
Brain Stimul. 2015 Sep-Oct;8(5):937-44
pubmed: 25981159
Nat Rev Neurosci. 2011 Oct 20;12(11):652-69
pubmed: 22011681
Brain Stimul. 2017 Jul - Aug;10(4):856-858
pubmed: 28363807
Drug Alcohol Depend. 2018 Apr 1;185:226-237
pubmed: 29471227
Neuropsychopharmacology. 2016 Dec;41(13):3032-3041
pubmed: 27374278
Brain Stimul. 2009 Jan;2(1):50-4
pubmed: 20539835
Neuroimage. 2017 Feb 1;146:395-403
pubmed: 27651067
Sci Rep. 2018 Feb 19;8(1):3253
pubmed: 29459743
Neurosci Biobehav Rev. 2014 Nov;47:592-613
pubmed: 25454360
Brain Struct Funct. 2015 Nov;220(6):3555-64
pubmed: 25156575
Front Psychiatry. 2018 Aug 31;9:368
pubmed: 30233420
Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12569-74
pubmed: 18723676
Schizophr Res. 2014 Mar;153(1-3):122-8
pubmed: 24529366
Expert Opin Drug Discov. 2014 Nov;9(11):1307-17
pubmed: 25195620
Radiologe. 2018 Nov;58(Suppl 1):34-39
pubmed: 28695243
Subst Abuse. 2010 Apr 7;2010(4):9-20
pubmed: 20485533
Bioanalysis. 2012 Jul;4(14):1787-804
pubmed: 22877223
Ann N Y Acad Sci. 2014 Oct;1327:79-93
pubmed: 25069523
J Neuroimmune Pharmacol. 2008 Sep;3(3):165-72
pubmed: 18521756
Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4165-6
pubmed: 23483010
Neuropsychopharmacology. 2017 Jan;42(2):437-445
pubmed: 27550732
Alcohol Clin Exp Res. 2016 Aug;40(8):1609-16
pubmed: 27439218
Neurosci Biobehav Rev. 2019 Jan;96:10-20
pubmed: 30439373
Front Psychiatry. 2018 Oct 15;9:478
pubmed: 30420814
JAMA Psychiatry. 2017 May 1;74(5):511-519
pubmed: 28297025
Neuropsychopharmacology. 2018 Jun;43(7):1498-1509
pubmed: 29511334
Neurosci Biobehav Rev. 2016 Oct;69:36-48
pubmed: 27450578
J Neurosci. 2016 Nov 16;36(46):11788-11794
pubmed: 27852785
Front Cell Neurosci. 2015 May 05;9:162
pubmed: 25999814
Neurosci Bull. 2017 Dec;33(6):747-756
pubmed: 29064064
Drug Alcohol Depend. 2017 May 1;174:98-105
pubmed: 28319755
Curr Top Behav Neurosci. 2012;11:199-251
pubmed: 22294088
Eur J Neurosci. 2003 Jun;17(11):2462-8
pubmed: 12814378
Am J Psychiatry. 2019 Feb 1;176(2):119-128
pubmed: 30336705
Schizophr Res. 2014 Aug;157(1-3):231-7
pubmed: 24906219
Neuropsychopharmacology. 2013 Jan;38(1):248-9
pubmed: 23147489